



King's Research Portal

Document Version
Peer reviewed version

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Arzouni, A. A., Vargas-Seymour, A., King, A., Nardi, N., & Jones, P. M. (Accepted/In press). Using mesenchymal stromal cells in islet transplantation. *Stem cells translational medicine*, 7(8), 559-563.

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Using mesenchymal stromal cells in islet transplantation

Ahmed A Arzouni, Andreia Vargas-Seymour, Nance Nardi¹, Aileen JF King and Peter M Jones²

Department of Diabetes, School of Life Course Sciences, Faculty of Life Sciences and Medicine,
King's College London, Guy's Campus, London SE1 1UL, UK.

¹Laboratory of Stem Cells and Tissue Engineering, Universidade Luterana do Brasil, Brazil

²Corresponding author

Peter M Jones

Department of Diabetes

School of Life Course Sciences

Faculty of Life Sciences and Medicine

King's College London

Guy's Campus, Hodgkin Building (HB2.10N)

London SE1 1UL

UK

peter.jones@kcl.ac.uk

+44(0)2078486273

Keywords

Mesenchymal stromal cell; islet transplantation; Type 1 diabetes; extracellular matrix; immunoregulation

Introduction

Islet transplantation and Type 1 diabetes

Type 1 diabetes mellitus (T1DM) is a chronic autoimmune disease characterised by hyperglycemia caused by insulin deficiency due to the selective destruction of β -cells within pancreatic islets of Langerhans. People with T1DM are dependent on the administration of exogenous insulin to survive, either by (multiple) daily injection or infusion. However, sporadic administration of exogenous insulin often fails to maintain tight glycaemic control, such that hyperglycemic and hypoglycemic excursions are common, both of which are associated with devastating side effects^{1,2}. β -cell replacement offers the potential for providing physiological glycemic control, so avoiding hyperglycemic and hypoglycemic episodes. Whole pancreas transplantation is surgically invasive and associated with significant co-morbidity³ whereas transplantation of the endocrine islets, which comprise only 2-3 % of the total pancreas, is a safe procedure with little or no co-morbidity⁴. Transplantation of isolated islets as a therapy for T1DM is therefore an attractive therapeutic option.

The UK islet Transplant Consortium (UKITC) was established in 2000 and the UK National Health Service established the first government-funded islet transplant service focused on people with T1DM with severe hypoglycemia unawareness. Worldwide, over 1,500 people with T1DM have now received intraportal islet transplantation in 40 centres (<https://citregistry.org/content/citr-9th-annual-report>). Islet transplantation outcomes have improved year-on-year^{5,6}, with recent reports that approximately 50 % of graft recipients remain insulin independent at 5 years and more, which places the success rate of islet transplantation on par with that of whole pancreas transplantation⁷.

Current issues with islet transplantation

The availability of islet transplantation as a therapeutic option to a wider population of people with T1D is severely limited by a shortage of tissue donors. Current isolation techniques recover only around half of the islets from a pancreas, so a single transplantation requires multiple donors. The scarcity of donor islets is exacerbated by the loss of functional islets during the islet isolation and pre-implantation culture period due to ischemia, physical and oxidative stresses and the deleterious effects of inflammatory cytokines. Culturing human islets for 24-72 h prior to transplantation has been adopted by most islet transplant centres. This allows for the initiation of time-dependent immunosuppressive regimens in the graft recipient and enables quality control testing of the donor islets and their shipment to distant transplantation centres. However, maintaining islet viability after isolation remains challenging. It is well documented that islets deteriorate rapidly during culture^{8,9}, with reported average losses of 20 % of the islet cell mass after 20 h, and occasional losses of > 50 % of the islet cell mass resulting in the cancellation of the planned transplantation procedure¹⁰. There is also convincing evidence that a substantial proportion of the functional islet graft (up to 80 %) is lost in the immediate post-transplantation period (24-48 h), because of deleterious responses of transplanted islet cells to a hypoxic, inflammatory, immunogenic host environment¹¹. Strategies which improve the functional survival of islets both before and after transplantation will improve the outcome of individual grafts, and also enable the limited pool of donor islets to treat many more people with T1DM by avoiding the current clinical practice of administering multiple grafts to achieve normoglycemia⁵. Genetic manipulation strategies have been reported to improve the survival and/or function of transplanted islets¹², but this is unlikely to be acceptable in clinical-grade human transplant

material, whereas autologous, cell-based treatments are clinically attractive. One emerging strategy is the use of mesenchymal stromal cells (MSCs) to take advantage of their anti-inflammatory, immunoregulatory, angiogenic and regenerative properties. *This Perspective will focus on the potential of MSC-derived soluble mediators to improve transplantation outcomes primarily by influencing graft function rather than affecting the host environment.*

Mesenchymal stromal cells

The International Society for Cellular Therapy has designated the term ‘multipotent mesenchymal stromal cells’ (MSCs) to refer to cells often referred to previously as mesenchymal stem cells, which can be isolated from bone marrow and many other tissues including adipose, placenta, cord blood and the ocular limbus. To define cells as MSCs they must meet three main criteria¹³. First, cells must be plastic-adherent when maintained in standard culture conditions. Second, $\geq 95\%$ of cells must express CD105, CD73 and CD90, whilst they must lack hematopoietic antigen expression that includes CD45, CD34, CD14 or CD11b, CD79 α or CD19 and HLA class II. Finally, MSCs must be capable of trilineage differentiation potential into osteoblasts, adipocytes and chondroblasts under the standard differentiation conditions *in vitro*.

Mesenchymal stromal cells and islet transplantation

MSCs are currently being investigated as adjuvants to improve the outcomes of islet transplantation. It is well established from studies in other tissues that MSCs play a major role in tissue repair by migrating to the site of injury and depositing extracellular matrix (ECM) which acts as a repair scaffold and as a reservoir for a wide range of MSC-derived biologically

active molecules with anti-inflammatory, immunomodulatory and angiogenic properties¹¹⁻¹³, all of which might be predicted to enhance the functional survival of islet grafts.

Studies in rodent models of diabetes have demonstrated that co-transplanting MSCs with islets improves the outcome of islet transplantation in terms of glycemic control¹⁴⁻¹⁹. These beneficial effects have been attributed to the ability of MSCs to enhance revascularisation^{17,20} or to suppress the host immune responses to the graft²¹⁻²³. However, MSCs also improve transplantation outcomes of syngenic grafts¹⁷, which do not provoke an immune response, and in microencapsulated islet grafts¹⁸, which do not revascularise, suggesting that MSCs improve graft outcomes via multiple mechanisms.

Many of these *in vivo* islet transplantation studies use the renal subcapsular graft site because it is surgically accessible, it facilitates the anatomical co-localisation of islets and MSCs, and it enables surgical retrieval of the graft material (and thus reversion to hyperglycemia) by unilateral nephrectomy. However, clinical islet transplantation is almost exclusively via the hepatic portal vein, which does not facilitate co-engraftment of islets and MSCs. Thus, after intraportal delivery the islets (100-200 μm diameter) lodge in the hepatic microcirculation where they re-vascularise, while the much smaller MSCs (15-30 μm) pass through the liver and most likely end up in the lung microcirculation²⁴. Attempts to co-localise islets and MSCs by generating islet:MSC composites have shown limited efficacy *in vitro* with no significant improvement in the *in vivo* transplantation outcomes in diabetic mice⁴⁶.

An alternative strategy to co-transplanting islets and MSCs is a pre-transplantation co-culture period *in vitro* to enhance islet functional survival before their subsequent engraftment, and several different configurations have been used to investigate the functional effects of co-

culture, as shown in Figure 1. Direct contact co-culture of islets with MSCs is consistently reported to improve glucose-stimulated insulin secretion (GSIS), whether configured as monolayer MSCs, or in suspension culture as composites^{25–28}. However, discrepancies in the effect of MSCs on islet function have been observed in studies using indirect, non-contact co-culture systems (Figure 1), with some reporting MSC-dependent improvements in GSIS^{17,29}, and others reporting no effects^{32–34}. The efficacy of direct contact co-culture strategies may be due, at least in part, to the ability of MSCs to secrete abundant amounts of ECM³⁰ which interacts with localised islet cells. Thus, elastin microfibril interface 1 (EMILIN-1) and integrin-linked protein kinase (ILK-1) were reported to be highly expressed in MSCs populations with islet regenerative capabilities³¹, implicating ECM-integrin interactions in mediating the beneficial effects of MSCs on islet function. Consistent with this, MSCs which support islet function secrete protein matrix metalloproteases (MMP1 and MMP13) that are involved in ECM remodelling³², and co-culture of mouse and human islets with de-cellularized MSC-derived ECM is alone sufficient to improve GSIS²⁴.

The ECM secreted by MSCs acts not only as a physical scaffold but also as a reservoir for numerous biologically active molecules to influence the function and regeneration of the surrounding tissues³³. Mass spectrometry analysis of human bone marrow MSC-derived ECM³³ has identified a wide range of secretory products, including growth factors and anti-inflammatory molecules, which reinforces the notion of MSC-derived ECM acting as a “mobile drug dispensary” for tissue regeneration. Indeed, many of the factors implicated in the beneficial effects on islets are associated with MSC-derived ECM³³ (Table 1). This, in turn, raises the possibility of utilising MSC-derived molecules (see Table 1) to improve islet graft function without the requirement for delivering MSCs as part of the graft material. We have

recently used a non-biased qRT-PCR strategy to screen MSC populations for the expression of peptide and protein ligands of G-protein-coupled receptors (GPCRs) known to be expressed by islet β -cells³⁴. The anti-inflammatory molecule annexin A1 (ANXA1) was identified as a highly expressed secretory product in both mouse³⁵ and human³⁶ MSC populations, and has been localised to MSC-derived ECM³⁶. Subsequent functional studies demonstrated that preculturing islets with exogenous ANXA1 improved GSIS *in vitro*^{24,26}, protected islet cells against cytokine-induced apoptosis³⁵, and improved their ability to regulate glycaemia in diabetic mice³⁵. However, ANXA1 is not the sole mechanism through which MSCs influence islet function since genetic deletion or siRNA-induced knockdown of ANXA1 in MSCs impaired, but did not completely abolish, their capacity to enhance islet function³⁵. Two other molecules which are highly expressed by MSCs - stromal cell-derived factor1/C-X-C motif chemokine 12(SDF-1/CXCL12) and collagen type III alpha 1 (Col III A1) - are also reported to have beneficial effects on islet function³⁷, and CXCL12 has been reported to enhance islet graft survival and function in a mouse model of diabetes³⁸. This raises the possibility of defining a “cocktail” of MSC-derived molecules which mimics the beneficial effects of MSC co-culture on islet function, and which therefore offers the prospect of cell-free treatment of islet populations during the isolation and pre-transplantation culture periods.

Translation to clinical human islet transplantation protocols

The use of a precisely-defined cocktail of MSC-derived products could overcome many of the technical hurdles of cellular therapy, such as upscaling MSC production whilst maintaining a stable phenotype, quality control between different MSC populations, the establishment of reliable safety and efficacy profiles, and the challenges of *in vitro* co-culture of MSCs and human islets on the scale required for clinical transplantation. MSC-derived products can be

manufactured in GMP conditions, and evaluated for safety, dosage and potency in a manner similar to that applied to current pharmaceuticals. Indeed, several of these MSC biotherapeutic molecules and/or their receptors are currently under investigation for their therapeutic potential in other clinical situations^{39–41}.

A cell-free “cocktail” treatment of islets prior to transplantation may also offer regulatory advantages over cell-based adjuvant therapy. In the UK, human islets for clinical transplantation are covered by the Tissues and Cells Directive (2004/23/EC) and are considered as graft material rather than medicinal products by the Human Tissue Authority, so are exempt from the stringent regulations covering new medicinal products. If, as seems likely, pre-treating islets with MSC biotherapeutic molecules is maintaining their functional viability rather than inducing any fundamental modification they will continue to be classified as graft material rather than a medicinal product. Thus, for example, the biotherapeutic cocktail could be used as a supplement to the islet culture medium in an analogous manner to the inclusion of human serum albumin which is beneficial for islet survival since it neutralises endogenous pancreatic enzymes⁴². Translation of current experimental studies into modifications to clinical human islet transplantation protocols may therefore be relatively straightforward in regulatory terms.

Summary and conclusions.

There is a convincing body of experimental evidence demonstrating that MSCs can exert beneficial effects on the outcomes of islet transplantation as a therapy for T1D. Most likely through a number of different mechanisms involving MSC-derived molecules having direct effects on the islet graft to improve its functional survival, and on the host environment to suppress inflammatory and immune responses to the graft. The MSC-dependent effects on the graft material may be mimicked, to some extent, by defined modifications to pre-transplantation culture protocols, offering a simple and effective means of improving the clinical outcomes of islet transplantation.

Acknowledgments

Our work on MSCs and islet transplantation has been supported by an MRC Doctoral Training Program studentship (AAA), a CAPES Fellowship from the Government of Brazil (AV-S), and a project grant support from Diabetes UK (PMJ, AJK DUK 15/0005146).




Figure 1 Different co-culture systems for islets and MSCs.

A) Direct contact co-culture system ⁴⁵, where MSCs are seeded in adherent monolayers in a treated tissue culture dish and islets are placed in direct contact on the layer of MSCs. B) Direct contact co-culture system ²⁵, where MSCs are seeded in a non-treated culture and maintained in suspension culture with islets. C) Indirect co-culture system ¹⁷, in this system, MSCs are seeded as adherent monolayers into the bottom of a transwell treated culture dish and islets are placed into the insert in the upper compartment of the well.



Table 1 Proposed mechanisms of action for MSCs to improve islet function

Author/year	MSCs	Proposed underlying mechanisms modulating islet functional viability
Arzouni et al 2017 ³⁶	Human adipose-derived MSCs	Annexin A1 MSC-derived extracellular matrix
Lavoie et al 2016 ³¹	Human bone marrow -derived MSCs	EMILIN-1 ILK-1
Rackham et al 2016 ³⁵	Mouse adipose-derived MSC	Annexin A1
Yamada et al 2014 ²⁹	Human adipose-derived MSCs	VEGF
Bell et al 2012 ³²	Human umbilical cord blood/ Bone Marrow-derived MSCs	Matrix metalloproteases (MMPs) Transforming growth factor-beta (TGF-beta) Epidermal growth factor receptor (EGFR)-activating ligands
Park et al 2010 ^{17,43}	Human umbilical cord blood-derived MSCs	Interleukin-6 (IL-6) Hepatocyte growth factor (HGF) TGF-beta Vascular endothelial growth factor-A (VEGF-A)
Karaoz et al 2010 ⁴⁴	Rat bone marrow-derived MSCs	IL-6 TGF-beta1 Fibronectin (FN) Phosphoprotein1 (SSP1)

Bibliography

1. Geddes J, Schopman JE, Zammitt NN, Frier BM. Prevalence of impaired awareness of hypoglycaemia in adults with Type 1 diabetes. *Diabet. Med.* 2008;25(4):501-504. doi:10.1111/j.1464-5491.2008.02413.x.
2. McCrimmon RJ, Sherwin RS. Hypoglycemia in type 1 diabetes. *Diabetes* 2010;59(10):2333-2339. doi:10.2337/db10-0103.
3. Dholakia S, Royston E, Quiroga I, et al. The rise and potential fall of pancreas transplantation. *Br Med Bull* 2017;124(1):171-179. doi:10.1093/bmb/ldx039.
4. Shapiro AMJ, Pokrywczynska M, Ricordi C. Clinical pancreatic islet transplantation. *Nat. Rev. Endocrinol.* 2016;13(5):268-277. doi:10.1038/nrendo.2016.178.
5. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. *N. Engl. J. Med.* 2000;343(4):230-238. doi:10.1056/NEJM200007273430401.
6. Ryan EA, Paty BW, Senior PA, et al. Five-year follow-up after clinical islet transplantation. *Diabetes* 2005;54(7):2060-2069.
7. Gruessner AC. 2011 update on pancreas transplantation: comprehensive trend analysis of 25,000 cases followed up over the course of twenty-four years at the International Pancreas Transplant Registry (IPTR). *Rev. Diabet. Stud.* 2011;8(1):6-16. doi:10.1900/RDS.2011.8.6.
8. Matsumoto S, Zhang G, Qualley S, et al. Analysis of donor factors affecting human islet isolation with current isolation protocol. *Transplant Proc* 2004;36(4):1034-1036. doi:10.1016/j.transproceed.2004.04.013.
9. Bottino R, Balamurugan AN, Bertera S, Pietropaolo M, Trucco M, Piganelli JD.

Preservation of human islet cell functional mass by anti-oxidative action of a novel SOD mimic compound. *Diabetes* 2002;51(8):2561-2567.

10. Kin T, Senior P, O’Gorman D, Richer B, Salam A, Shapiro AMJ. Risk factors for islet loss during culture prior to transplantation. *Transpl Int* 2008;21(11):1029-1035. doi:10.1111/j.1432-2277.2008.00719.x.
11. Kanak MA, Takita M, Kunnathodi F, Lawrence MC, Levy MF, Naziruddin B. Inflammatory response in islet transplantation. *Int J Endocrinol* 2014;2014:451035. doi:10.1155/2014/451035.
12. Mahato RI. Gene expression and silencing for improved islet transplantation. *J. Control. Release* 2009;140(3):262-267. doi:10.1016/j.jconrel.2009.04.011.
13. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy* 2006;8(4):315-317. doi:10.1080/14653240600855905.
14. Borg DJ, Weigelt M, Wilhelm C, et al. Mesenchymal stromal cells improve transplanted islet survival and islet function in a syngeneic mouse model. *Diabetologia* 2014;57(3):522-531. doi:10.1007/s00125-013-3109-4.
15. Yoshimatsu G, Sakata N, Tsuchiya H, et al. The co-transplantation of bone marrow derived mesenchymal stem cells reduced inflammation in intramuscular islet transplantation. *PLoS One* 2015;10(2):e0117561. doi:10.1371/journal.pone.0117561.
16. Hayward JA, Ellis CE, Seeberger K, et al. Co-transplantation of Mesenchymal Stem Cells with Neonatal Porcine Islets Improve Graft Function in Diabetic Mice. *Diabetes* 2017;66(5):1312-1321. doi:10.2337/db16-1068.
17. Park K-S, Kim Y-S, Kim J-H, et al. Trophic molecules derived from human mesenchymal stem cells enhance survival, function, and angiogenesis of isolated islets after

transplantation. *Transplantation* 2010;89(5):509-517.

doi:10.1097/TP.0b013e3181c7dc99.

18. Rackham CL, Chagastelles PC, Nardi NB, Hauge-Evans AC, Jones PM, King AJF. Co-transplantation of mesenchymal stem cells maintains islet organisation and morphology in mice. *Diabetologia* 2011;54(5):1127-1135. doi:10.1007/s00125-011-2053-4.
19. Kerby A, Jones ES, Jones PM, King AJ. Co-transplantation of islets with mesenchymal stem cells in microcapsules demonstrates graft outcome can be improved in an isolated-graft model of islet transplantation in mice. *Cytotherapy* 2013;15(2):192-200. doi:10.1016/j.jcyt.2012.10.018.
20. Ito T, Itakura S, Todorov I, et al. Mesenchymal stem cell and islet co-transplantation promotes graft revascularization and function. *Transplantation* 2010;89(12):1438-1445.
21. Fiorina P, Jurewicz M, Augello A, et al. Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. *J. Immunol.* 2009;183(2):993-1004. doi:10.4049/jimmunol.0900803.
22. Xu DM, Yu XF, Zhang D, et al. Mesenchymal stem cells differentially mediate regulatory T cells and conventional effector T cells to protect fully allogeneic islet grafts in mice. *Diabetologia* 2012;55(4):1091-1102. doi:10.1007/s00125-011-2433-9.
23. Ding Y, Xu D, Feng G, Bushell A, Muschel RJ, Wood KJ. Mesenchymal stem cells prevent the rejection of fully allogeneic islet grafts by the immunosuppressive activity of matrix metalloproteinase-2 and -9. *Diabetes* 2009;58(8):1797-1806. doi:10.2337/db09-0317.
24. Eggenhofer E, Benseler V, Kroemer A, et al. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. *Front. Immunol.* 2012;3:297. doi:10.3389/fimmu.2012.00297.
25. Jung E-J, Kim S-C, Wee Y-M, et al. Bone marrow-derived mesenchymal stromal cells

- support rat pancreatic islet survival and insulin secretory function in vitro. *Cytotherapy* 2011;13(1):19-29. doi:10.3109/14653249.2010.518608.
26. Rackham CL, Dhadda PK, Chagastelles PC, et al. Pre-culturing islets with mesenchymal stromal cells using a direct contact configuration is beneficial for transplantation outcome in diabetic mice. *Cytotherapy* 2013;15(4):449-459. doi:10.1016/j.jcyt.2012.11.008.
 27. Scuteri A, Donzelli E, Rodriguez-Menendez V, et al. A double mechanism for the mesenchymal stem cells' positive effect on pancreatic islets. *PLoS One* 2014;9(1):e84309. doi:10.1371/journal.pone.0084309.
 28. Karaoz E, Ayhan S, Okçu A, et al. Bone marrow-derived mesenchymal stem cells co-cultured with pancreatic islets display β cell plasticity. *J Tissue Eng Regen Med* 2011;5(6):491-500. doi:10.1002/term.342.
 29. Yamada S, Shimada M, Utsunomiya T, et al. Trophic effect of adipose tissue-derived stem cells on porcine islet cells. *J. Surg. Res.* 2014;187(2):667-672. doi:10.1016/j.jss.2013.10.031.
 30. de Souza BM, Bouças AP, Oliveira FDS de, et al. Effect of co-culture of mesenchymal stem/stromal cells with pancreatic islets on viability and function outcomes: a systematic review and meta-analysis. *Islets* 2017;9(2):30-42. doi:10.1080/19382014.2017.1286434.
 31. Lavoie JR, Creskey MM, Muradia G, et al. Brief Report: Elastin Microfibril Interface 1 and Integrin-Linked Protein Kinase Are Novel Markers of Islet Regenerative Function in Human Multipotent Mesenchymal Stromal Cells. *Stem Cells* 2016;34(8):2249-2255. doi:10.1002/stem.2385.
 32. Bell GI, Meschino MT, Hughes-Large JM, Broughton HC, Xenocostas A, Hess DA.

- Combinatorial human progenitor cell transplantation optimizes islet regeneration through secretion of paracrine factors. *Stem Cells Dev.* 2012;21(11):1863-1876. doi:10.1089/scd.2011.0634.
33. Prewitz MC, Seib FP, von Bonin M, et al. Tightly anchored tissue-mimetic matrices as instructive stem cell microenvironments. *Nat. Methods* 2013;10(8):788-794. doi:10.1038/nmeth.2523.
34. Amisten S, Salehi A, Rorsman P, Jones PM, Persaud SJ. An atlas and functional analysis of G-protein coupled receptors in human islets of Langerhans. *Pharmacol. Ther.* 2013;139(3):359-391. doi:10.1016/j.pharmthera.2013.05.004.
35. Rackham CL, Vargas AE, Hawkes RG, et al. Annexin A1 Is a Key Modulator of Mesenchymal Stromal Cell-Mediated Improvements in Islet Function. *Diabetes* 2016;65(1):129-139. doi:10.2337/db15-0990.
36. Arzouni AA, Vargas-Seymour A, Rackham CL, et al. Mesenchymal stromal cells improve human islet function through released products and extracellular matrix. *Clin. Sci.* 2017;131(23):2835-2845. doi:10.1042/CS20171251.
37. Dunér P, Al-Amily IM, Soni A, et al. Adhesion G Protein-Coupled Receptor G1 (ADGRG1/GPR56) and Pancreatic β -Cell Function. *J. Clin. Endocrinol. Metab.* 2016;101(12):4637-4645. doi:10.1210/jc.2016-1884.
38. Chen T, Yuan J, Duncanson S, et al. Alginate encapsulant incorporating CXCL12 supports long-term allo- and xenoislet transplantation without systemic immune suppression. *Am. J. Transplant.* 2015;15(3):618-627. doi:10.1111/ajt.13049.
39. Berlanga-Acosta J, Gavilondo-Cowley J, López-Saura P, et al. Epidermal growth factor in clinical practice - a review of its biological actions, clinical indications and safety implications. *Int. Wound J.* 2009;6(5):331-346. doi:10.1111/j.1742-481X.2009.00622.x.

40. Margolis DJ, Crombleholme T, Herlyn M. Clinical protocol: Phase I trial to evaluate the safety of H5.020CMV.PDGF-B for the treatment of a diabetic insensate foot ulcer. *Wound Repair Regen.* 2000;8(6):480-493.
41. Wrangle JM, Patterson A, Johnson CB, et al. IL-2 and Beyond in Cancer Immunotherapy. *J. Interferon Cytokine Res.* 2018;38(2):45-68. doi:10.1089/jir.2017.0101.
42. Nacher M, Estil Les E, Garcia A, et al. Human serum versus human serum albumin supplementation in human islet pretransplantation culture: in vitro and in vivo assessment. *Cell Transplant.* 2016;25(2):343-352. doi:10.3727/096368915X688119.
43. Park KS, Kim YS, Kim JH, et al. Influence of human allogenic bone marrow and cord blood-derived mesenchymal stem cell secreting trophic factors on ATP (adenosine-5'-triphosphate)/ADP (adenosine-5'-diphosphate) ratio and insulin secretory function of isolated human islets from cadaveric donor. *Transplant Proc* 2009;41(9):3813-3818. doi:10.1016/j.transproceed.2009.06.193.
44. Karaoz E, Genç ZS, Demircan PÇ, Aksoy A, Duruksu G. Protection of rat pancreatic islet function and viability by coculture with rat bone marrow-derived mesenchymal stem cells. *Cell Death Dis.* 2010;1:e36. doi:10.1038/cddis.2010.14.
45. Rackham CL, Dhadda PK, Le Lay AM, King AJF, Jones PM. Preculturing Islets With Adipose-Derived Mesenchymal Stromal Cells Is an Effective Strategy for Improving Transplantation Efficiency at the Clinically Preferred Intraportal Site. *Cell Med.* 2014;7(1):37-47. doi:10.3727/215517914X680047.
46. Rackham CL, Dhadda PK, Simpson S, Godazgar M, King AJF, Jones PM. Composite Mesenchymal Stromal Cell Islets: Implications for transplantation via the clinically-preferred Intraportal route. *Transplantation Direct* 2018, in press.

